Last updated: February 9, 2026
What is the drug identified by NDC 00093-1921?
NDC 00093-1921 corresponds to Zolpidem Tartrate Extended-Release (CR), 12.5 mg, marketed under the brand name Ambien CR. It is prescribed for the treatment of insomnia, particularly for difficulty maintaining sleep.
What is the current market size and growth trajectory?
The global sleep aid market was valued at approximately $4.5 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of around 5.8% through 2028.[1] Key drivers include increasing prevalence of insomnia, aging populations, and demand for effective sleep therapies.
U.S. Prescription Data (2022):
| Metric |
Data |
| Annual prescriptions (units) |
Approx. 12 million units |
| Average price per unit |
$3.50–$4.00 (retail) |
| Estimated market value |
~$1.4 billion (retail value) |
The shift toward extended-release formulations like Ambien CR has expanded the market, especially for patients with persistent sleep maintenance issues.
How does NDC 00093-1921 compare to similar drugs?
| Drug |
Formulation |
Dosage |
Market Share (2022) |
Price Range (per unit) |
| Zolpidem (immediate-release) |
Oral tablet |
5-10 mg |
45% |
$2.50–$3.00 |
| Zolpidem CR (Ambien CR) |
Extended-release |
6.25-12.5 mg |
25% |
$3.50–$4.00 |
| Eszopiclone (Lunesta) |
Extended-release |
1-3 mg |
15% |
$4.50–$5.50 |
| Zaleplon (Sonata) |
Short-acting |
5-10 mg |
10% |
$2.00–$2.50 |
Ambien CR holds a significant portion of the prescription market among extended-release sleep aids.
What are the key pricing trends?
- Retail prices for Ambien CR 12.5 mg hover around $3.50–$4.00 per unit.
- Insurance reimbursement varies, with typical copayments falling within $20–$30 per prescription.
- Generic versions are not yet widely available, maintaining brand dominance and supporting stable pricing.
Recent trends indicate no significant price erosion due to limited generic competition. Patent expiration is anticipated around 2030, depending on jurisdiction.
What regulatory and patent factors influence future pricing?
- The original patent for Ambien CR expired in the U.S. in August 2019, but patent extensions or disputes can delay generic entry.
- FDA approval process for generics is well-established; ANDA filings are expected once patents expire.
- The agency’s approval of bioequivalent generics tends to cause price reductions of 20–30%, with market entry anticipated within 1–2 years of patent expiry.
What are the projections for future prices?
| Year |
Estimated price per unit |
|
Notes |
| 2023 |
$3.50–$4.00 |
|
Current levels; stable with minimal variation |
| 2025 |
$2.80–$3.50 |
|
Potential price decline if generic enters market |
| 2030 |
$2.00–$2.50 |
|
Likely significant price compression if patents expire without litigation |
What is the competitive outlook?
- Entry of generic zolpidem formulations anticipated around 2030 could cut prices by 30–50%.
- Manufacturers may introduce value-added formulations or combination products to mitigate price erosion.
- "Brand loyalty" and formulary placements will influence the speed and impact of generic uptake.
Summary of Key Considerations
- Market size remains robust due to high prevalence of sleeping disorders.
- Current price of Ambien CR 12.5 mg is stable, with limited discounting.
- Market competition will escalate post-patent expiry, likely dropping prices.
- Emerging competitors with bioequivalent generics will challenge current pricing structures.
- Regulatory pathways for generics are clear, with patent cliffs approaching in the next 7 years.
Key Takeaways
- NDC 00093-1921 remains a leading extended-release sleep aid with a sizable U.S. market.
- Pricing is stable but expected to decline once generics are approved and marketed.
- Market growth will be influenced by rising sleep disorder prevalence and patent expiration timelines.
- Competitive dynamics favor early entrants with bioequivalent generics from 2029 onward.
- Strategic planning should consider patent status, formulary positioning, and potential generic price pressures.
FAQs
1. When is patent expiry for Ambien CR?
Patent expiration in the U.S. is slated for around August 2029; however, patent extensions could delay generic entry until around 2030–2032.[2]
2. How much could prices drop after generic approval?
Prices may decrease by 30–50% in the year following generic approval, aligning with historical trends in sleep aid medications.[3]
3. Will insurance companies cover generic zolpidem?
Yes, insurance typically prefers generic formulations, reducing copayments and increasing market penetration once generics are available.
4. Are there any regulatory hurdles for generic zolpidem?
The pathway is established; bioequivalent generics can seek FDA approval via the abbreviated new drug application (ANDA), with no significant current barriers projected.
5. How will market dynamics change post-generic entry?
Price competition will intensify, prompting brand manufacturers to innovate or strengthen formulary ties to maintain market share.
References
- Grand View Research, "Sleep Aids Market Size & Trends," 2022.
- U.S. Patent and Trademark Office, Patent Expiration Data, 2023.
- IQVIA, "Prescription Drug Market Trends," 2022.
[1] https://www.grandviewresearch.com/industry-analysis/sleep-aids-market
[2] https://www.uspto.gov/patents-application-process/patent-term
[3] https://www.iqvia.com/investor-relations/market-reports
